参芪口服液联合西医常规方案治疗稳定型心绞痛的疗效及对TLR4/NF-κB信号通路的影响

玄继昌; 楚湘英; 岳文伟

doi:10.14009/j.issn.1672-2124.2022.12.011

您当前的位置：

首页 >

文章列表页 >

参芪口服液联合西医常规方案治疗稳定型心绞痛的疗效及对TLR4/NF-κB信号通路的影响

论著 | 更新时间：2023-04-16

- 参芪口服液联合西医常规方案治疗稳定型心绞痛的疗效及对TLR4/NF-κB信号通路的影响
- Efficacy of Shenqi Oral Liquid Combined with Conventional Western Medicine Regimen in the Treatment of Stable Angina Pectoris and Its Effects on TLR4/NF-κB Signaling Pathway
- 中国医院用药评价与分析 2022年第12期页码：1476-1479
- 作者机构：
  
  1. 济宁医学院附属医院邹城院区心内科
  2. 山东第一医科大学第三附属医院急诊科
  3. 山东第一医科大学第三附属医院心内科
- 作者简介：
- 基金信息：
  
  山东省中医药科技发展计划项目（No.2019-00867）
- DOI：10.14009/j.issn.1672-2124.2022.12.011
  中图分类号： R541.4
- 纸质出版日期：2022，
扫描看全文
玄继昌, 楚湘英, 岳文伟. 参芪口服液联合西医常规方案治疗稳定型心绞痛的疗效及对TLR4/NF-κB信号通路的影响[J]. 中国医院用药评价与分析, 2022,(12):1476-1479.

XUAN Jichang, CHU Xiangying, YUE Wenwei. Efficacy of Shenqi Oral Liquid Combined with Conventional Western Medicine Regimen in the Treatment of Stable Angina Pectoris and Its Effects on TLR4/NF-κB Signaling Pathway[J]. 2022,(12):1476-1479.
玄继昌, 楚湘英, 岳文伟. 参芪口服液联合西医常规方案治疗稳定型心绞痛的疗效及对TLR4/NF-κB信号通路的影响[J]. 中国医院用药评价与分析, 2022,(12):1476-1479. DOI： 10.14009/j.issn.1672-2124.2022.12.011.

XUAN Jichang, CHU Xiangying, YUE Wenwei. Efficacy of Shenqi Oral Liquid Combined with Conventional Western Medicine Regimen in the Treatment of Stable Angina Pectoris and Its Effects on TLR4/NF-κB Signaling Pathway[J]. 2022,(12):1476-1479. DOI： 10.14009/j.issn.1672-2124.2022.12.011.

摘要

目的：探讨参芪口服液联合西医常规方案治疗稳定型心绞痛（SAP）的疗效及对Toll样受体4（TLR4）/核因子κB（NF-κB）信号通路的影响。方法：选取2020年2月至2021年6月济宁医学院附属医院邹城院区心内科收治的SAP患者108例，根据临床病例随机表分为联合组（n=54）、对照组（n=54）。对照组患者采用西医常规方案治疗，联合组患者在西医常规方案治疗的基础上加用参芪口服液。比较两组患者的心电图疗效、不良反应，治疗前、治疗4周后的心绞痛症状（心绞痛发作频率、持续时间）、血液流变学指标[血浆黏度（PV）、纤维蛋白原（FIB）和红细胞聚集指数（RCAI）]水平、T淋巴细胞亚群（CD3

、CD4

/CD8

）水平及外周血单核细胞TLR4、NF-κB mRNA相对表达量。结果：联合组患者的总有效率高于对照组[92.59%（50/54）vs. 75.93%（41/54）]

差异有统计学意义（P＜0.05）。治疗4周后，两组患者心绞痛发作频率均减少，持续时间均缩短；联合组患者发作频率少于对照组，持续时间短于对照组，差异均有统计学意义（P＜0.05）。治疗4周后，两组患者的PV、FIB和RCAI水平，以及外周血单核细胞TLR4、NF-κB mRNA相对表达量降低，且联合组患者低于对照组，差异均有统计学意义（P＜0.05）。治疗4周后，两组患者的CD3

、CD4

和CD4

/CD8

水平均升高，且联合组患者高于对照组；两组患者CD8

水平降低，且联合组患者低于对照组，差异均有统计学意义（P＜0.05）。联合组、对照组患者的不良反应发生率比较[7.41%（4/54）vs. 5.56%（3/54）]

差异无统计学意义（P＞0.05）。结论：参芪口服液联合西医常规方案治疗SAP的效果显著，可有效改善患者心绞痛症状及血液流变学，抑制TLR4/NF-κB信号通路激活，调节免疫功能，安全性高。

Abstract

OBJECTIVE: To probe into the efficacy of Shenqi oral liquid combined with conventional western medicine regimen in the treatment of stable angina pectoris（SAP） and its effects on Toll-like receptor 4（TLR4）/monocyte nuclear factor-κB（NF-κB） signaling pathway. METHODS: A total of 108 patients with SAP admitted into Department of Cardiology

Zoucheng Hospital

Affiliated Hospital of Jining Medical College from Feb. 2020 to Jun. 2021 were extracted to be divided into the combination group（n=54） and control group（n=54） according to the randomized table of clinical cases. The control group was treated with conventional western medicine

while the combination group received Shenqi oral liquid on the basis of conventional western medicine. The efficacy of electrocardiogram

adverse drug reactions

the symptoms of angina pectoris（frequency and duration of angina pectoris）

blood rheology indicators [plasma viscosity（PV）

fibrinogen（FIB）

erythrocyte aggregation index（RCAI）]

T lymphocyte subsets（CD3

CD4

/CD8

）

the relative expression of TLR4 and NF-κB mRNA in peripheral blood mononuclear cells before treatment and after treatment of 4 weeks were compared between two groups. RESULTS: The total effective rate of combination group was higher than that of control group [92.59%（50/54） vs. 75.93%（41/54）]

the difference was statistically significant（P

0.05）. After treatment of 4 weeks

the frequency and duration of angina pectoris decreased in both groups. The frequency in the combination group was less than that in the control group

and the duration was shorter than that in the control group

with statistically significant difference（P

0.05）. After treatment of 4 weeks

the relative expressions of PV

FIB and RCAI

TLR4 and NF-κB mRNA in peripheral blood mononuclear cells decreased in both groups

and the combination group was lower than in the control group

the differences were statistically significant（P

0.05）. After treatment of 4 weeks

the levels of CD3

CD4

and CD4

/CD8

increased in both groups

and the combination group was higher than the control group; the level of CD8

decreased in two groups

and the combination group was lower than the control group

the differences were statistically significant（P

0.05）. There was no significant difference in the incidence of adverse drug reactions between the combination group and control group [7.41%（4/54） vs. 5.56%（3/54）

0.05]. CONCLUSIONS: The efficacy of Shenqi oral liquid combined with conventional western medicine regimen in the treatment of SAP is significant

which can effectively improve the symptoms and hemorheology of patients with angina pectoris

inhibit the activation of TLR4/NF-κB signaling pathway

regulate the immune function with higher safety.

关键词

参芪口服液稳定型心绞痛TLR4/NF-κB信号通路免疫功能

Keywords

references

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

柴胡桂枝汤加减治疗稳定型心绞痛伴抑郁状态的疗效及对血清炎症因子和miR-126的影响

益生菌辅助治疗初治菌阳肺结核的临床研究